205 related articles for article (PubMed ID: 31000477)
21. Combination anti-HIV antibodies provide sustained virological suppression.
Sneller MC; Blazkova J; Justement JS; Shi V; Kennedy BD; Gittens K; Tolstenko J; McCormack G; Whitehead EJ; Schneck RF; Proschan MA; Benko E; Kovacs C; Oguz C; Seaman MS; Caskey M; Nussenzweig MC; Fauci AS; Moir S; Chun TW
Nature; 2022 Jun; 606(7913):375-381. PubMed ID: 35650437
[TBL] [Abstract][Full Text] [Related]
22. Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial.
Venter WDF; Moorhouse M; Sokhela S; Serenata C; Akpomiemie G; Qavi A; Mashabane N; Arulappan N; Sim JW; Sinxadi PZ; Wiesner L; Maharaj E; Wallis C; Boyles T; Ripin D; Stacey S; Chitauri G; Hill A
Lancet HIV; 2019 Jul; 6(7):e428-e437. PubMed ID: 31202690
[TBL] [Abstract][Full Text] [Related]
23. Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial.
Molina JM; Grund B; Gordin F; Williams I; Schechter M; Losso M; Law M; Ekong E; Mwelase N; Skoutelis A; Wiselka MJ; Vandekerckhove L; Benfield T; Munroe D; Lundgren JD; Neaton JD;
Lancet HIV; 2018 Apr; 5(4):e172-e180. PubMed ID: 29352723
[TBL] [Abstract][Full Text] [Related]
24. Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial.
Krupitsky E; Blokhina E; Zvartau E; Verbitskaya E; Lioznov D; Yaroslavtseva T; Palatkin V; Vetrova M; Bushara N; Burakov A; Masalov D; Mamontova O; Langleben D; Poole S; Gross R; Woody G
Lancet HIV; 2019 Apr; 6(4):e221-e229. PubMed ID: 30880163
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
Lataillade M; Lalezari JP; Kozal M; Aberg JA; Pialoux G; Cahn P; Thompson M; Molina JM; Moreno S; Grinsztejn B; Diaz RS; Castagna A; Kumar PN; Latiff GH; De Jesus E; Wang M; Chabria S; Gartland M; Pierce A; Ackerman P; Llamoso C
Lancet HIV; 2020 Nov; 7(11):e740-e751. PubMed ID: 33128903
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial.
Maranda B; Labbé SM; Lurquin M; Brabant P; Fugère A; Larrivée JF; Grbic D; Leroux A; Leduc F; Finzi A; Gaudreau S; Swart Y;
Lancet Infect Dis; 2024 Jan; 24(1):25-35. PubMed ID: 37619584
[TBL] [Abstract][Full Text] [Related]
27. A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study.
Miller WC; Hoffman IF; Hanscom BS; Ha TV; Dumchev K; Djoerban Z; Rose SM; Latkin CA; Metzger DS; Lancaster KE; Go VF; Dvoriak S; Mollan KR; Reifeis SA; Piwowar-Manning EM; Richardson P; Hudgens MG; Hamilton EL; Sugarman J; Eshleman SH; Susami H; Chu VA; Djauzi S; Kiriazova T; Bui DD; Strathdee SA; Burns DN
Lancet; 2018 Sep; 392(10149):747-759. PubMed ID: 30191830
[TBL] [Abstract][Full Text] [Related]
28. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E
Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial.
ENCORE1 Study Group
Lancet; 2014 Apr; 383(9927):1474-1482. PubMed ID: 24522178
[TBL] [Abstract][Full Text] [Related]
30. BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial.
Butler K; Inshaw J; Ford D; Bernays S; Scott K; Kenny J; Klein N; Turkova A; Harper L; Nastouli E; Paparini S; Choudhury R; Rhodes T; Babiker A; Gibb D
Health Technol Assess; 2016 Jun; 20(49):1-108. PubMed ID: 27377073
[TBL] [Abstract][Full Text] [Related]
31. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.
Corey L; Gilbert PB; Juraska M; Montefiori DC; Morris L; Karuna ST; Edupuganti S; Mgodi NM; deCamp AC; Rudnicki E; Huang Y; Gonzales P; Cabello R; Orrell C; Lama JR; Laher F; Lazarus EM; Sanchez J; Frank I; Hinojosa J; Sobieszczyk ME; Marshall KE; Mukwekwerere PG; Makhema J; Baden LR; Mullins JI; Williamson C; Hural J; McElrath MJ; Bentley C; Takuva S; Gomez Lorenzo MM; Burns DN; Espy N; Randhawa AK; Kochar N; Piwowar-Manning E; Donnell DJ; Sista N; Andrew P; Kublin JG; Gray G; Ledgerwood JE; Mascola JR; Cohen MS;
N Engl J Med; 2021 Mar; 384(11):1003-1014. PubMed ID: 33730454
[TBL] [Abstract][Full Text] [Related]
32. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
[TBL] [Abstract][Full Text] [Related]
33. Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.
Mills AM; Rizzardini G; Ramgopal MN; Osiyemi OO; Bogner JR; Hagins DP; Paredes R; Reynes J; Rockstroh JK; Carr A; Su FH; Klopfer SO; Eves K; Plank RM; Correll T; Fox MC
Lancet HIV; 2024 Jun; 11(6):e357-e368. PubMed ID: 38734016
[TBL] [Abstract][Full Text] [Related]
34. Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study.
Cohen YZ; Butler AL; Millard K; Witmer-Pack M; Levin R; Unson-O'Brien C; Patel R; Shimeliovich I; Lorenzi JCC; Horowitz J; Walsh SR; Lin S; Weiner JA; Tse A; Sato A; Bennett C; Mayer B; Seaton KE; Yates NL; Baden LR; deCamp AC; Ackerman ME; Seaman MS; Tomaras GD; Nussenzweig MC; Caskey M
PLoS One; 2019; 14(8):e0219142. PubMed ID: 31393868
[TBL] [Abstract][Full Text] [Related]
35. Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption.
Wang CY; Wong WW; Tsai HC; Chen YH; Kuo BS; Lynn S; Blazkova J; Clarridge KE; Su HW; Lin CY; Tseng FC; Lai A; Yang FH; Lin CH; Tseng W; Lin HY; Finstad CL; Wong-Staal F; Hanson CV; Chun TW; Liao MJ
N Engl J Med; 2019 Apr; 380(16):1535-1545. PubMed ID: 30995373
[TBL] [Abstract][Full Text] [Related]
36. Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial.
Molina JM; Yazdanpanah Y; Afani Saud A; Bettacchi C; Chahin Anania C; DeJesus E; Olsen Klopfer S; Grandhi A; Eves K; Robertson MN; Correll T; Hwang C; Hanna GJ; Sklar P
Lancet HIV; 2021 Jun; 8(6):e324-e333. PubMed ID: 34000227
[TBL] [Abstract][Full Text] [Related]
37. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Wohl DA; Yazdanpanah Y; Baumgarten A; Clarke A; Thompson MA; Brinson C; Hagins D; Ramgopal MN; Antinori A; Wei X; Acosta R; Collins SE; Brainard D; Martin H
Lancet HIV; 2019 Jun; 6(6):e355-e363. PubMed ID: 31068270
[TBL] [Abstract][Full Text] [Related]
38. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
39. Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial.
Wijting I; Rokx C; Boucher C; van Kampen J; Pas S; de Vries-Sluijs T; Schurink C; Bax H; Derksen M; Andrinopoulou ER; van der Ende M; van Gorp E; Nouwen J; Verbon A; Bierman W; Rijnders B
Lancet HIV; 2017 Dec; 4(12):e547-e554. PubMed ID: 29107562
[TBL] [Abstract][Full Text] [Related]
40. Modeling HIV-1 Within-Host Dynamics After Passive Infusion of the Broadly Neutralizing Antibody VRC01.
Cardozo-Ojeda EF; Perelson AS
Front Immunol; 2021; 12():710012. PubMed ID: 34531859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
